IP Library Patent Application 18415561
Patent Application
App. No. 18/415,561

COMBINATION DOSAGE FORMS AND ADMINISTRATION THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/415,561
Abstract

This disclosure relates to methods of administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.

Claims (16)

1 .- 24 . (canceled)

25 . A dosage form, comprising from about 5 mg to about 30 mg of a tetrabenazine and (S)-bupropion or (R)-bupropion, wherein the dosage form is a solid or a liquid dosage form, and wherein the tetrabenazine is not deuterium-modified.

26 . The dosage form of claim 25 , wherein the dosage form is a solid dosage form.

27 . The dosage form of claim 25 , comprising from about 70 mg to about 140 mg of the (S)-bupropion or (R)-bupropion.

28 . The dosage form of claim 25 , comprising from about 10 mg to about 15 mg of the tetrabenazine.

29 . The dosage form of claim 28 , comprising from about 90 mg to about 110 mg of the (S)-bupropion or (R)-bupropion.

30 . The dosage form of claim 25 , comprising from about 90 mg to about 110 mg of the (S)-bupropion or (R)-bupropion.

31 . The dosage form of claim 25 , comprising(S)-bupropion.

32 . The dosage form of claim 31 , wherein the (S)-bupropion has an enantiomeric excess of at least 97%.

33 . The dosage form of claim 25 , comprising from about 70 mg to about 100 mg of the (S)-bupropion or (R)-bupropion.

34 . The dosage form of claim 25 , comprising from about 100 mg to about 140 mg of the (S)-bupropion or (R)-bupropion.

35 . The dosage form of claim 25 , comprising from about 9 mg to about 12 mg of the tetrabenazine.

36 . The dosage form of claim 25 , comprising from about 12 mg to about 15 mg of the tetrabenazine.

37 . The dosage form of claim 25 , wherein the (S)-bupropion or (R)-bupropion is not deuterium-modified.

38 . The dosage form of claim 25 , comprising from about 70 mg to about 140 mg of(S)-bupropion.

39 . The dosage form of claim 38 , wherein the (S)-bupropion is not deuterium-modified.

Assignments (2)
SECURITY INTEREST Recorded May 9, 2025
From: AXSOME THERAPEUTICS, INC.; AXSOME MALTA LTD.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 071247/0836 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 9, 2024
From: TABUTEAU, HERRIOT
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 067667/0352 →